Administrative Aspects of Molecular Diagnostics-Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment Models.

IF 4.7 3区 医学 Q1 ONCOLOGY JCO oncology practice Pub Date : 2024-11-01 Epub Date: 2024-11-12 DOI:10.1200/OP.23.00812
Lalan Wilfong, Lauren Baggett, Philip Reena, Regina Murphy, Harpreet Singh, Paul Kluetz, Brooke Byrd, Robert McDonough, Shirisha Reddy, Rogelio Roger Brito
{"title":"Administrative Aspects of Molecular Diagnostics-Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment Models.","authors":"Lalan Wilfong, Lauren Baggett, Philip Reena, Regina Murphy, Harpreet Singh, Paul Kluetz, Brooke Byrd, Robert McDonough, Shirisha Reddy, Rogelio Roger Brito","doi":"10.1200/OP.23.00812","DOIUrl":null,"url":null,"abstract":"<p><p>This paper discusses the administrative aspects of molecular diagnostics in oncology, including US Food and Drug Administration (FDA) oversight, the regulatory approval process, clinical, and operational workflows, and payment models. Comprehensive molecular testing is important to deliver optimal oncology care and improve patient outcomes. Despite the potential benefits of testing, utilization remains low. The FDA regulatory approval process is reviewed for in vitro diagnostic products, which includes classification into three regulatory classes on the basis of risk. Companion diagnostic devices are used to guide treatment decisions. The clinical and operational challenges associated with molecular testing in oncology are also discussed, including the rapidly evolving landscape of precision oncology, the wide range of biomarker testing options, and complexities of test ordering, interpretation, and result delivery. There is a need for a multifaceted support approach involving education, technology enhancements, and workflow support to overcome these challenges. In terms of payment models, coverage policies between Medicare and commercial payers are compared with differences in coverage criteria, with Medicare focusing on FDA approval or clearance, whereas commercial payers consider additional factors such as National Comprehensive Cancer Network and ASCO guidelines. Commercial payers tend to cover smaller panels on the basis of guideline-recommended biomarkers, whereas coverage for broad tumor profiling is limited. Several strategies can increase the utilization of molecular testing, including integrating test results into electronic medical record platforms, standardizing billing practices, increasing clinical trials, and primary literature supporting the use of molecular testing, educating physicians, and using tumor boards for result interpretation and treatment discussions.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":"20 11","pages":"1501-1507"},"PeriodicalIF":4.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP.23.00812","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This paper discusses the administrative aspects of molecular diagnostics in oncology, including US Food and Drug Administration (FDA) oversight, the regulatory approval process, clinical, and operational workflows, and payment models. Comprehensive molecular testing is important to deliver optimal oncology care and improve patient outcomes. Despite the potential benefits of testing, utilization remains low. The FDA regulatory approval process is reviewed for in vitro diagnostic products, which includes classification into three regulatory classes on the basis of risk. Companion diagnostic devices are used to guide treatment decisions. The clinical and operational challenges associated with molecular testing in oncology are also discussed, including the rapidly evolving landscape of precision oncology, the wide range of biomarker testing options, and complexities of test ordering, interpretation, and result delivery. There is a need for a multifaceted support approach involving education, technology enhancements, and workflow support to overcome these challenges. In terms of payment models, coverage policies between Medicare and commercial payers are compared with differences in coverage criteria, with Medicare focusing on FDA approval or clearance, whereas commercial payers consider additional factors such as National Comprehensive Cancer Network and ASCO guidelines. Commercial payers tend to cover smaller panels on the basis of guideline-recommended biomarkers, whereas coverage for broad tumor profiling is limited. Several strategies can increase the utilization of molecular testing, including integrating test results into electronic medical record platforms, standardizing billing practices, increasing clinical trials, and primary literature supporting the use of molecular testing, educating physicians, and using tumor boards for result interpretation and treatment discussions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分子诊断的管理方面--监督、监管审批流程、临床和运营工作流程以及支付模式。
本文讨论了肿瘤分子诊断的管理问题,包括美国食品药品管理局(FDA)的监督、监管审批程序、临床和操作工作流程以及支付模式。全面的分子检测对于提供最佳肿瘤治疗和改善患者预后非常重要。尽管检测具有潜在益处,但利用率仍然很低。美国食品及药物管理局(FDA)对体外诊断产品的监管审批流程进行了审查,其中包括根据风险分为三个监管类别。辅助诊断设备用于指导治疗决策。此外,还讨论了与肿瘤分子检测相关的临床和操作挑战,包括快速发展的精准肿瘤学、广泛的生物标记物检测选择,以及检测订购、解释和结果交付的复杂性。需要采取多方面的支持方法,包括教育、技术改进和工作流程支持,以克服这些挑战。在支付模式方面,比较了医疗保险和商业支付机构的承保政策与承保标准的差异,医疗保险侧重于美国食品及药物管理局的批准或许可,而商业支付机构则考虑国家综合癌症网络和 ASCO 指南等其他因素。商业支付机构倾向于根据指南推荐的生物标记物来支付较小的样本,而对广泛的肿瘤图谱分析的支付则很有限。有几种策略可以提高分子检测的利用率,包括将检测结果整合到电子病历平台、标准化计费方法、增加临床试验、支持使用分子检测的主要文献、教育医生以及利用肿瘤委员会进行结果解释和治疗讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.40
自引率
7.50%
发文量
518
期刊最新文献
Contextual Framework for Understanding Treatment De-Escalation in Patients With Breast Cancer. Reply to: The Value of Offering Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable. The Value of Offering Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1